Merck And Ridgeback Announce Publication Of Phase 3 Study Of Molnupiravir, An Investigational Oral Antiviral COVID-19 Treatment, In The New England Journal Of Medicine
Published by The Street By Business Wire Merck (MRK) – Get Merck & Co., Inc. Report, known as MSD outside the United States and Canada,